Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma

Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma ORIGINAL ARTICLE Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma Oskar Koperek, MD,* Christoph Kornauth, MD,* David Capper, MD,wz Anna Sophie Berghoff, MD,y Reza Asari, MD,8 Bruno Niederle, MD,8 Andreas von Deimling, MD,wz Peter Birner, MD, MSc,* and Matthias Preusser, MDy Key Words: papillary thyroid carcinoma, BRAF, V600E mutation Abstract: The V600E mutation of the B-type Raf kinase (BRAF) (Am J Surg Pathol 2012;36:844–850) gene is a common event in papillary thyroid carcinoma (PTC) and seems to play a key role in the development and progression of this disease. We evaluated the expression of the mutated BRAF V600E protein in 144 cases of PTC using a novel mu- apillary thyroid carcinoma (PTC) is the most common tation-specific antibody. Seventy-six PTCs (52.8%) showed un- Ptype of thyroid cancer. Mutation of the B-type Raf equivocal diffuse cytoplasmic expression of the mutated BRAF kinase (BRAF) is detected in 20% to 80% of sporadic PTCs protein, and the T1799A point mutation was confirmed by se- with higher prevalence in conventional PTC than in fol- quencing analysis in selected cases. No statistical difference in licular variants. The T1799A point mutation leading to V600E BRAF protein expression was seen between micro- V600E http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Surgical Pathology Wolters Kluwer Health

Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma

Loading next page...
 
/lp/wolters-kluwer-health/immunohistochemical-detection-of-the-braf-v600e-mutated-protein-in-hVaQzMGgkI

References (40)

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
0147-5185
eISSN
1532-0979
DOI
10.1097/PAS.0b013e318246b527
pmid
22592144
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma Oskar Koperek, MD,* Christoph Kornauth, MD,* David Capper, MD,wz Anna Sophie Berghoff, MD,y Reza Asari, MD,8 Bruno Niederle, MD,8 Andreas von Deimling, MD,wz Peter Birner, MD, MSc,* and Matthias Preusser, MDy Key Words: papillary thyroid carcinoma, BRAF, V600E mutation Abstract: The V600E mutation of the B-type Raf kinase (BRAF) (Am J Surg Pathol 2012;36:844–850) gene is a common event in papillary thyroid carcinoma (PTC) and seems to play a key role in the development and progression of this disease. We evaluated the expression of the mutated BRAF V600E protein in 144 cases of PTC using a novel mu- apillary thyroid carcinoma (PTC) is the most common tation-specific antibody. Seventy-six PTCs (52.8%) showed un- Ptype of thyroid cancer. Mutation of the B-type Raf equivocal diffuse cytoplasmic expression of the mutated BRAF kinase (BRAF) is detected in 20% to 80% of sporadic PTCs protein, and the T1799A point mutation was confirmed by se- with higher prevalence in conventional PTC than in fol- quencing analysis in selected cases. No statistical difference in licular variants. The T1799A point mutation leading to V600E BRAF protein expression was seen between micro- V600E

Journal

American Journal of Surgical PathologyWolters Kluwer Health

Published: Jun 1, 2012

There are no references for this article.